Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?
Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?
复制标题
DOI：
10.1016/j.ctro.2017.10.005
复制
发表时间：
2018-01-01
影响因子：
3.1
通讯作者：
Blanchard, Pierre
中科院分区：
文献类型：
--
作者：
Mirghani, Haitham;Blanchard, Pierre
HPV驱动的口咽癌的生存率明显高于烟草和酒精诱导的头颈癌。由于HPV阳性患者更年轻，更健康，更有可能存活下来，长期治疗副作用正成为一个主要问题。这导致科学和医学界重新评估目前的治疗方案，以开发毒性较小的策略，同时保持良好的肿瘤结果。在这篇文章中，我们讨论了正在进行的治疗降级试验，并强调了这些研究提出的问题。(C)2017作者由Elsevier爱尔兰有限公司代表欧洲放射治疗和肿瘤学会发布。
HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies. (C) 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and Oncology.